Different studies have evaluated the prognostic effect of ctDNA detection on localized breast cancer, including different subtypes of breast cancer (e.g., HR+/HER2+ breast cancer, triple negative breast cancer, among others). The gene discussed is ERBB2; the disease is breast cancer.